

Medivir - Liver Project Getting Ready to Deliver

Redeye still believes that, with the Medivir share trading at the same levels as a year ago, the stock market has not fully appreciated the company's progress. We see three main reasons to invest in Medivir: fostroxacitabine bralpamide, its partnered projects, and its non-licensed projects (to which we attach optional value). Its aim with fostroxacitabine is to bring chemotherapy to advanced liver cancer, while Medivir's flagship partnered candidate birinapant holds a licensing deal worth up to USD 350m plus royalties.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Medivir - Liver Project Getting Ready to Deliver